- Certain Birth Control Pills, Devices Linked to Higher Heart Risks
- Ready for a Romantic Relationship? Your Friends’ Opinions Matter
- More Sunshine in Pregnancy, Infancy Could Benefit Kids With MS
- Enjoying Valentine’s Day When a Loved One Has Alzheimer’s
- Could Yogurt Lower Your Odds for Deadly Colon Cancers?
- Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials
- Canned Tuna Recalled in Dozens of States Over Risk of Food Poisoning
- More Evidence Ozempic Can Curb Alcoholism
- In People With Autism, ADHD Rates Still Common in Adulthood
- Almost Half of Rural Americans Face Long Drives for Surgery
Xtoro Approved for Swimmer’s Ear

Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer’s ear, clinically known as acute otitis externa.
The infection of the outer ear and ear canal, most often caused by ear canal bacteria, has typical symptoms including pain, swelling, redness and discharge, the FDA said in a news release.
The drug’s safety and effectiveness were evaluated in a clinical study of more than 1,200 people, aged 6 months to 85 years. The most common side effects were ear itching and nausea.
Xtoro is produced by Alcon Laboratories, based in Fort Worth, Texas.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.